WHO-Aligned Molecular Classification
One Test. One Snapshot.
Complete Clarity.
The first integrated molecular profiling assay for endometrial cancer—delivering biology-driven
treatment decisions from a single tissue sample.
2,000 ×
Sequencing Depth
12-14 Days
Turnaround Time
6
Molecular Sub types
The Challenge
Fragmented Testing.
Fragmented Decisions.
Current workflows are sequential, slow, and tissue-intensive—leading to
delays and missed treatment opportunities.
Prolonged Turnaround
Molecular tests ordered sequentially across multiple labs. Results arrive at different times, delaying critical treatment decisions.
Over & Under Treatment
Without complete molecular context, POLE-mutated patients face unnecessary chemo while TP53-abnormal cases may be undertreated.
Tissue Exhaustion
Repeated testing consumes precious tissue—especially in small biopsies—leaving nothing for additional analyses when most needed.
Missed Therapies
Incomplete molecular profiling means patients may miss eligibility for immunotherapy, targeted therapy, or hormone therapy entirely.
"Endometrial cancer care can no longer afford fragmented diagnostics."
The Solution
A Single, Integrated Molecular Snapshot
OncoIndx 360° Endometrium replaces fragmented workflows with one comprehensive, biology-driven report that links molecular subtype to prognosis and treatment strategy.
Upfront, Integrated Testing
NGS + IHC + MSI performed together—not sequentially. Eliminates TAT delays and tissue exhaustion from the start.
Single Molecular Snapshot
One sample. One test. One report. No compromises. Aligned with ESGO/ESTRO/ESP guidance for early molecular classification.
Biology That Drives Decisions
Molecular subtypes are not just reported—they are interpreted and translated into actionable treatment pathways for each patient.
NSMP, Finally Actionable
ER-stratified NSMP classification transforms a “leftover category” into biologically meaningful, clinically actionable information.
Guidelines, Made Practical
Fully operationalizes ESGO/ESTRO/ESP and WHO molecular classification recommendations in real-world clinical practice.
Head-to-Head
Today's Pathway vs. OncoIndx® 360°
| Parameter | Today's Pathway | OncoIndx® 360° |
|---|---|---|
| Testing Approach | Sequential, fragmented, across multiple labs | ✓Upfront, integrated, single tissue sample |
| Molecular Coverage | Limited, often incomplete | ✓Complete (NGS + IHC + MSI) |
| Turnaround Time | Prolonged & unpredictable | ✓Predictable: 10–14 Days |
| Tissue Usage | High – risk of exhaustion | ✓Tissue-sparing — one sample for all |
| NSMP Interpretation | Ambiguous "diagnosis of exclusion" | ✓Actionable, ER-stratified biology |
| Treatment Decisions | Variable, morphology-driven | ✓Consistent, WHO-aligned, biology-driven |
WHO-Aligned Classification
Molecular Subtypes, Clinically Decoded
OncoIndx 360° evaluates all WHO-relevant molecular layers and classifies tumors into clinically actionable categories with clear prognosis and treatment implications.
POLE-ultramutated
Safe treatment de-escalation; avoid unnecessary chemotherapy even when histologically high-grade.
MMRd / MSI-High
Prioritize immunotherapy, with significant benefit expected from checkpoint inhibitor-based treatment regimens.
TP53-abnormal
Treatment escalation required. Intensive chemotherapy ± HER2-targeted therapy for aggressive biology.
NSMP — ER Positive
Hormone-based therapy with reduced cytotoxic exposure. Biologically distinct with better recurrence profile.
NSMP — ER Negative
Standard cytotoxic therapy with closer surveillance. Distinct risk profile from ER-positive NSMP.
HER2-positive
Precision escalation with HER2-targeted agents. Prognosis significantly improves with appropriate targeted therapy.
NSMP is no longer a "leftover category" — it is biologically stratified and clinically interpreted, driving real post-surgical decisions.
Get Started
Ready to Transform Cancer
Diagnostics?
Designed for oncologists managing complex, advanced and refractory cancer patients. Get more information about OncoIndx360 for your clinical setting.
Access OncoIndx 360° Endometrium Sample Reports & Case Studies
Fill in your details to explore real-world oncology insights…
Access OncoIndx 360° Endometrium Sample Reports & Case Studies
Fill in your details to explore real-world oncology insights…